BiondVax to Close Trading on NASDAQ on July

BiondVax to Close Trading on NASDAQ on July

BiondVax launches a new investor relations

website (www.biondvax.com) providing international investors with comprehensive information about the Company, progress

Ness Ziona, Israel - July 2, 2015

- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it will be closing trading on the NASDAQ

market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its

international investor relations program. This event will be the culmination of a week of meetings as part of a non-deal roadshow

with US-based institutional investors and financial analysts.

In addition, BiondVax today announced the

launch of its new investor relations website, which can be found at www.biondvax.com.

Institutional investors or analysts interested

in meeting with BiondVax management in New York or wishing to attend the market closing event should contact the Company's

investor relations team.

Ron Babecoff, BiondVax's President

and CEO, commented, "We are very much looking forward to launching our investor relations operations in the US. The closing

event at the NASDAQ is an excellent starting point and the culmination of a long and an important process for us, of listing our

shares in the United States, and by that making ourselves accessible to the US capital market."

About BiondVax Pharmaceuticals Ltd

BiondVax is an innovative biopharmaceutical

company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza

virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique,

proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system

for a cross-protecting and long-lasting effect.

Forward Looking Statements

This press release contains forward-looking

statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe,"

"intend," "plan," "continue," "may," "will," "anticipate," and similar

expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties

reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties

and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals

Ltd. Risks and uncertainties include, but are not limited to, risks inherent in the development and commercialization of potential

products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks,

uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission,

including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to

update or revise any forward-looking statements.

For further information, please contact: